In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome

Ernesto Bosch, Iván Valencia, Ernesto Escudero et al. · Fertility and Sterility · 2003 · 347 citations · Full text

Medicine, Gynecology, Obstetrics +16

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation

K. Diedrich, C. Diedrich, Eduarda M. Santos et al. · Human Reproduction · 1994 · 310 citations

Medicine, Endocrinology, Gynecology +17

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group

Human Reproduction · 1998 · 293 citations · Full text

Pharmacy, Endocrinology, Pharmacology +17

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

Margo R. Fluker, J. Grifo, Arthur Leader et al. · Fertility and Sterility · 2001 · 241 citations

Medicine, Endocrinology, Gynecology +9

Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer

Evangelos Papanikolaou, Efstratios M. Κolibianakis, Cristina Pozzobon et al. · Fertility and Sterility · 2007 · 165 citations

Veterinary Medicine, Gynecology, Obstetrics +11